DIXIE BRANDS, INC. TAPS TEAM OF PET EXPERTS TO LAUNCH VETERINARIAN FORMULATED PET WELLNESS LINE, THERABIS
DENVER, CO (August 24, 2015): Dixie Brands, Inc. (Dixie), a leader in emerging cannabinoid extraction and wellness platforms and TBSK, LLC an entrepreneurial innovation company led by 30-year veterinarian, Dr. Stephen M. Katz VMD, have collaborated to bring to the $3.2B Natural Pet Foods, Treats & Supplements market a new line of pet wellness products called Therabis. These new products will target the most common pet challenges of separation anxiety and itching in addition to improving joint mobility and flexibility. The partnership pairs Dixie’s deep history as one of the first companies to establish the healthful hemp market with the 2012 launch of its Dixie Botanicals, with TBSK’s proprietary pet wellness formula that has been tried, tested and improved over the past 10 years in Dr. Katz’s veterinary hospital in the Bronx, New York.
The mission of Therabis is to foster the unconditional love between pets and families, which is grounded in the belief that strengthening that bond enhances the human condition.
The Company intends to bring the remarkable power of hemp to the pet market by combining key cannabinoids with other all-natural ingredients such as hemp powder and zinc, allowing pet owners to address the most uncomfortable of pet health issues with an all-natural solution. All three formulations will come in size and pet-specific pre-measured sachets, which can be added to any food product. Flavored with a blend of all-natural ingredients that has seen almost 100% palatability, the Therabis formulation is designed to deliver benefits from the very first time the product is used.
“Today’s launch of Therabis is the culmination of a dream I have had for 10 years to bring support to pets, and their owners, around the world, for some of the most common challenges they face,” said Dr. Katz, President of Therabis. “While it may sound lofty, we truly believe that the simple, but beautiful bond of love between a pet and its owner, actually has the power to make us better as people and to improve the human condition. It is that unique relationship which drives most pet owners to do anything they can to help their pets when they suffer. We developed the Therabis formulations with that very much in mind as we hope to provide pet owners with a healthy, natural way to make every day the best day possible for their pet. It is an honor and privilege to share our 10 years of research with a broader audience; and it is our hope that Therabis can play a role in elevating the health and wellness of pets and their owners.”
Therabis will be undergoing clinical trials at the University of Pennsylvania School of Veterinarian Medicine as well as field trials in over a dozen hospitals in New York. Both the field and clinical trials will be used for additional product development and to provide specific efficacy metrics. Dr Katz added, “The field and clinical trials will provide both quantitative analysis and anecdotal observation of our products. In combining both time tested natural ingredients with cutting edge cannabinoids, we have produced uniquely effective assistance for some of the most troublesome pet challenges.”
Therabis will be available in November of 2015 via http://www.therabis.com, and eventually the Company intends to distribute via veterinarian practices and retail outlets around the country. For pet owners who wish to stay informed, please visit the site to sign up for updates, and for the opportunity to receive a free trial product.
Dixie Brands Expands Cannabinoid Platform
In conjunction with today’s launch of Therabis, Dixie Brands, Inc. also announced that it is bringing to market a human cannabinoid wellness product called Aceso, whose name is derived from the Greek Goddess of the healing process. Aceso intends to bring the power of cannabinoids to the next level, allowing more people to more accurately find a whole plant formula that will optimize their health. All products will be developed using a specific ratio of ingredients in a proprietary cannabinoid formulation, as well as other synergistic compounds, delivered in a carefully measured, single serving oral spray or powder format (which can be mixed with water and/or other liquids) for fast and efficient delivery of health benefits. Aceso will be available for purchase at http://www.myaceso.com by early November. Click here to read the full release.
“Dixie Brands believes strongly that the future of cannabis extends far beyond THC-based products and today’s announcements are indicative of a critical ‘next-step’ implementation of Dixie Brands’ expansion strategy,” said Tripp Keber, CEO of Dixie Brands, Inc. “To date, we have achieved great success with our initial Dixie Elixirs and Edibles line, but we have always aspired to bring the potential of this amazing plant to a more mass level through development of a comprehensive suite of products and brands grounded in science and research. I am extremely proud of the teams of smart, dedicated and mutually aligned individuals who are helping to bring that vision to fruition and we look forward to many more exciting announcements in the future.”
ABOUT DIXIE BRANDS, INC.
Located in Denver, Colorado, Dixie Brands, Inc., (Dixie) through its affiliates across the country, has been formulating and producing award-winning THC and CBD-infused products since 2009. What began as a single flagship product, the Dixie Elixir (a THC-infused soda), has now expanded to over 30 different products across over 100 SKUs, representing the industry’s finest edibles, tinctures, topicals and connoisseur grade extractions. To find out more about Dixie’s innovative products, or about how Dixie is building the future of cannabis, please visit us at http://www.dixiebrands.com.
ABOUT TBSK, LLC
Located in Scottsdale, Arizona, TBSK, LLC was formed in 2015 to develop innovative products in the legal cannabis industry by Dr. Katz; Tony Alfiere, a cannabis industry expert; Bruce Arlen and Ty Bowers, branding and design professionals; Steven Trenk, Principal of Lizada Capital and active cannabis industry investor; James Sharkey, PhD chemist and Andi Gold, a finance executive.